Pyxis Oncology

We're pleased to announce that our CEO, Lara S. Sullivan, M.D., recently participated in a thought-provoking podcast with Joseph Coletti of RBC Capital Markets. In this insightful discussion, Lara delved into the capital market's understanding of Phase 1 trials, described our unique lead ADC asset, PYX-201, and provided a glimpse into what drives Pyxis Oncology forward. We're proud to share the Pyxis Oncology journey with a broader audience. This podcast is a must-listen if you're interested in gaining valuable insights into the complexities and nuances of early drug development. Be sure to check out the full podcast on Apple, Spotify and YouTube Music: https://lnkd.in/eFG8GVNr #Leadership #Innovation #Podcast #RBC #IndustryInsights #FutureForward #BusinessGrowth #ADC

#PYXS is excited to welcome Michael A. Metzger to our board. Mr. Metzger’s deep knowledge of the biopharmaceutical landscape and experience building companies will be invaluable as we continue clinical development of our lead #ADC asset, PYX-201. #PeopleofPYXS Read more here: https://lnkd.in/ern3vyk2

Our President and CEO, Lara S. Sullivan, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6 at 9:00 AM ET. A webcast and replay of the fireside chat will be available on the Events and Presentations section of our website, pyxisoncology.com. #JefferiesHealthcare

Today, #PYXS reported our Q1 2024 financial results, provided a corporate update and welcomed new Chief Business Officer, Stephen Worsley. Read more: tinyurl.com/3cp2ea2u

Our President and CEO, Lara S. Sullivan, M.D., will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14 at 3:05 PM ET. A webcast and replay of the fireside chat will be available on the Events and Presentations section of our website, pyxisoncology.com.

#PYXS CEO Lara S. Sullivan, M.D. had the opportunity to sit down with Brad Canino, Equity Research Analyst, during the Stifel 2024 Virtual Targeted Oncology Forum, to share her enthusiasm around our lead #AntibodyDrugConjugate asset, PYX-201. Click here to hear the update about our novel, first-in-class, and first-in-concept #ADC: https://lnkd.in/eGaNRAYP

We were excited to share our latest preclinical data at #AACR24, supporting our PYX-201 and PYX-106 programs. Two posters were presented for PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradomain-B Fibronectin (EDB+FN) target. Abstract #: 742 described broad, deep, and durable anti-tumor activity across a large panel of preclinical PDX models representing ten tumor types. Abstract #: 2908 detailed the development of an IHC assay to detect EDB+FN protein and a novel scoring method to quantify expression in tumor stroma. EDB+FN is broadly and predominantly expressed in tumor-induced stroma across multiple cancer indications (10 tumor types) with virtually no expression in healthy tissues. One poster was presented for PYX-106, Abstract #: 1373, exploring gene expression correlations between immune checkpoint molecules Siglec-15 and PD-L1 across various tumor types. The expression of Siglec-15 and PD-L1 positively correlated in certain cancer types, such as thyroid cancer, NSCLC, and head and neck cancer. Learn more: https://lnkd.in/eMZ7v8rG #AACR #AACR2024 #PeopleofPYXS #ADC #IO

This morning, #PYXS announced financial results for the fourth quarter and full year 2023 and provided a corporate update, which included approval of a seventh dose cohort in our ongoing Phase 1 study of our lead #AntibodyDrugConjugate asset, PYX-201.  Read more: https://lnkd.in/eqNmevVz  #AntibodyDrugConjugate #ADC #biotech  

#PYXS is excited to welcome Santhosh Palani, PhD, CFA to our board. Dr. Palani's background as a successful private and public healthcare investor and a drug developer will be invaluable as we continue clinical development of our lead #ADC asset, PYX-201, and our #IO asset, PYX-106. #PeopleofPYXS Read more here: https://lnkd.in/gXUH5cFi

#PYXS is excited to share our latest preclinical data at the upcoming #AACR conference in April. Four posters have been accepted! Learn more: https://lnkd.in/e8pG-T53